SPAC57A7.06 Antibody

What is SPAC57A7.06 and what cellular functions does it serve in S. pombe?

SPAC57A7.06 (UniProt ID: P87137) is a protein found in Schizosaccharomyces pombe (fission yeast strain 972/ATCC 24843). While comprehensive functional studies are still emerging, this protein is believed to play roles in cellular processes typical of the S. pombe model organism. The corresponding antibody (CSB-PA311230XA01SXV) has been developed specifically to target this protein, enabling researchers to investigate its localization, expression patterns, and potential interactions .

For experimental applications, it's important to note that this antibody was raised in rabbits against recombinant SPAC57A7.06 protein, making it suitable for various detection methods in fission yeast research. When designing experiments, researchers should consider that species reactivity is limited to S. pombe (strain 972/ATCC 24843) .

What are the optimal storage and handling conditions for maintaining SPAC57A7.06 antibody activity?

Proper storage and handling of SPAC57A7.06 antibody is critical for maintaining its specificity and sensitivity. Upon receipt, the antibody should be stored at either -20°C or -80°C . Repeated freeze-thaw cycles should be strictly avoided as they can lead to antibody degradation and loss of activity.

For optimal performance, consider implementing the following evidence-based practices drawn from antibody preservation research:

These recommendations parallel best practices used for preserving highly specific antibodies like those targeting HIV-1 envelope proteins, where activity preservation is critical for experimental reproducibility .

What validation methods should be employed to confirm SPAC57A7.06 antibody specificity?

Rigorous validation of antibody specificity is essential for obtaining reliable experimental results. For SPAC57A7.06 antibody, a multi-faceted validation approach is recommended:

• Genetic controls: Test antibody reactivity in wild-type versus SPAC57A7.06 knockout or knockdown S. pombe strains. The absence or reduction of signal in mutant strains strongly supports antibody specificity.

• Peptide competition assays: Pre-incubate the antibody with excess purified SPAC57A7.06 recombinant protein or peptide before application. Specific binding will be blocked, resulting in signal reduction.

• Western blot analysis: Verify that the antibody detects a band of the expected molecular weight on immunoblots. Multiple bands may indicate cross-reactivity or post-translational modifications.

• Orthogonal methods: Compare antibody-based detection with orthogonal techniques such as mass spectrometry or RNA expression analysis.

This comprehensive validation approach draws from methodologies used to verify broadly neutralizing antibodies, where researchers employed multiple techniques to confirm binding specificity and epitope recognition .

How can I optimize immunoprecipitation protocols for SPAC57A7.06 antibody in yeast cells?

Optimizing immunoprecipitation (IP) protocols for yeast proteins requires special considerations due to the robust cell wall and unique cellular components. For SPAC57A7.06 antibody:

• Cell lysis optimization: Use glass bead disruption in combination with enzymatic methods (such as zymolase treatment) to ensure complete cell breakage without denaturing the target protein.

• Buffer composition: For S. pombe proteins, consider a lysis buffer containing:

  • 50 mM HEPES pH 7.5

  • 150 mM NaCl

  • 1 mM EDTA

  • 1% Triton X-100

  • Protease inhibitor cocktail optimized for yeast

• Antibody concentration titration: Test a range of antibody concentrations (typically 2-10 μg per sample) to determine optimal binding while minimizing non-specific interactions.

• Pre-clearing step: Always include a pre-clearing step with protein A/G beads and non-immune serum to reduce non-specific binding.

• Incubation conditions: Extend antibody-lysate incubation time (4-16 hours at 4°C) to accommodate slower binding kinetics that might be present with yeast proteins.

This methodology incorporates principles used in the isolation of broadly neutralizing antibodies from complex samples, where careful optimization of binding conditions was critical for specificity .

What strategies can address weak or inconsistent signals when using SPAC57A7.06 antibody in immunofluorescence?

When facing weak or inconsistent signals in immunofluorescence experiments with SPAC57A7.06 antibody, consider these methodological interventions:

• Fixation optimization: Test multiple fixation methods, as epitope accessibility can vary dramatically:

  • 4% paraformaldehyde (15-20 minutes)

  • Methanol (-20°C, 10 minutes)

  • Combined formaldehyde/methanol approaches

• Antigen retrieval: Implement mild heat or enzymatic antigen retrieval methods to expose epitopes that may be masked during fixation.

• Signal amplification: Consider tyramide signal amplification or secondary antibody enhancement systems for low-abundance proteins.

• Permeabilization optimization: For yeast cells specifically, test different permeabilization reagents and durations:

  • 0.1-0.5% Triton X-100 (5-15 minutes)

  • 0.05-0.1% SDS (1-2 minutes)

  • Enzymatic digestion of cell wall components

• Blocking optimization: Use 5% BSA or 5-10% normal serum from the species of the secondary antibody to reduce background.

These approaches draw from principles used in detecting conformational epitopes in complex antigens, where signal optimization was critical for accurate detection .

How can I distinguish between specific and non-specific binding patterns when interpreting SPAC57A7.06 antibody results?

Distinguishing specific from non-specific binding is a critical aspect of antibody-based experiments. Implement these analytical approaches:

• Control inclusion: Always run parallel experiments with:

  • Secondary antibody only (no primary)

  • Non-immune IgG from the same species as SPAC57A7.06 antibody

  • Blocked antibody (pre-incubated with antigen)

• Pattern analysis: Specific binding typically shows distinct subcellular localization patterns consistent with protein function, while non-specific binding often appears as diffuse staining or irregular aggregates.

• Correlation with multiple methods: Confirm localization or expression patterns using orthogonal approaches:

• Validated positive controls: Include samples with known expression patterns of SPAC57A7.06 or related proteins.

This multi-faceted approach to specificity validation mirrors techniques used to confirm the binding specificity of broadly neutralizing antibodies against diverse viral variants .

What experimental approaches can determine SPAC57A7.06 protein interactions with other cellular components?

To characterize protein interactions of SPAC57A7.06, consider these methodological approaches:

• Co-immunoprecipitation (Co-IP): Use SPAC57A7.06 antibody to pull down the protein and its interacting partners from S. pombe lysates, followed by mass spectrometry identification.

• Proximity labeling: Fuse SPAC57A7.06 to BioID or APEX2 to label proximal proteins for subsequent purification and identification.

• Yeast two-hybrid screening: Use SPAC57A7.06 as bait to screen for interacting proteins from a S. pombe cDNA library.

• Fluorescence resonance energy transfer (FRET): Tag SPAC57A7.06 and suspected interaction partners with appropriate fluorophores to detect interactions in vivo.

For Co-IP experiments specifically, the following workflow is recommended:

• Harvest S. pombe cells in mid-log phase (OD600 ~0.5-0.8)

• Lyse cells in buffer containing 1% NP-40 or Triton X-100

• Pre-clear lysate with Protein A/G beads

• Incubate with SPAC57A7.06 antibody (5 μg) overnight at 4°C

• Capture with Protein A/G beads, wash 4-5 times

• Elute and analyze by SDS-PAGE followed by mass spectrometry

This approach incorporates principles used in characterizing epitope-antibody interactions in broadly neutralizing antibody research, where precise interaction mapping was essential .

How can post-translational modifications of SPAC57A7.06 be detected and characterized?

Post-translational modifications (PTMs) can significantly impact protein function. To detect and characterize PTMs on SPAC57A7.06:

• Immunoprecipitation coupled with mass spectrometry:

  • Use SPAC57A7.06 antibody to purify the protein

  • Perform tryptic digestion

  • Analyze by LC-MS/MS with specific settings to detect common PTMs

  • For comprehensive analysis, consider techniques like:

    • Phospho-enrichment for phosphorylation

    • Lectin affinity for glycosylation

    • Ubiquitin remnant motif antibodies for ubiquitination

• Western blotting with modification-specific antibodies:

  • After immunoprecipitation with SPAC57A7.06 antibody

  • Probe with antibodies against common PTMs (phospho-Ser/Thr/Tyr, acetyl-Lys, etc.)

• Mobility shift assays:

  • Compare migration patterns before and after treatment with:

    • Phosphatase for phosphorylation

    • Glycosidases for glycosylation

    • Deubiquitinating enzymes for ubiquitination

• Site-directed mutagenesis validation:

  • Mutate predicted modification sites

  • Compare function and modification status with wild-type protein

These approaches parallel methodologies used for characterizing antibody glycosylation patterns, where careful analysis of post-translational modifications significantly impacted antibody function .

How does SPAC57A7.06 antibody performance compare between different experimental techniques?

The performance of SPAC57A7.06 antibody varies across experimental applications, with important implications for experimental design:

When selecting an application, consider that conformational epitopes may be preserved differently across techniques. For example, native conditions in immunoprecipitation may better maintain protein structure compared to the denaturing conditions of Western blotting.

This comparative analysis draws from principles used in evaluating broadly neutralizing antibodies across multiple assay platforms, where assay-specific performance characteristics were critical for accurate interpretation .

What considerations should guide the choice between SPAC57A7.06 antibody and genetic tagging approaches?

Choosing between antibody-based detection and genetic tagging requires careful consideration of experimental goals:

• Antibody-based detection advantages:

  • Studies native protein without modification

  • No genetic manipulation required

  • Can specifically target post-translational modifications

  • Suitable for clinical or field samples

• Genetic tagging advantages:

  • Often higher specificity

  • Live-cell imaging capability

  • Consistent detection across experiments

  • Often works when antibodies are unavailable

• Decision matrix for experimental design:

This comparative assessment incorporates principles from therapeutic antibody development, where careful consideration of detection methods significantly impacted experimental outcomes and interpretations .

How might new antibody engineering approaches improve SPAC57A7.06 detection and analysis?

Emerging antibody technologies could enhance SPAC57A7.06 research:

• Single-domain antibodies (nanobodies): Smaller size (15 kDa vs. 150 kDa) allows better penetration into complex yeast samples and potentially better access to restricted epitopes.

• Recombinant antibody fragments: Fab, scFv, or single-domain fragments can provide more consistent performance across experiments with reduced background.

• Site-specific conjugation: Next-generation labeling strategies could improve sensitivity through controlled fluorophore placement, orientation, and stoichiometry.

• Affinity maturation: In vitro evolution techniques could enhance SPAC57A7.06 antibody binding characteristics, potentially improving detection limits.

• Bispecific formats: Dual-targeting antibodies could simultaneously detect SPAC57A7.06 and interacting partners, providing direct evidence of protein complexes.

These approaches draw from advanced antibody engineering methods used in developing therapeutic and broadly neutralizing antibodies, where precise molecular optimization has led to dramatic improvements in specificity and sensitivity .

What analytical frameworks can integrate SPAC57A7.06 antibody data with other -omics approaches?

To maximize research impact, SPAC57A7.06 antibody data should be integrated with complementary -omics datasets:

• Multi-omics integration platforms:

  • Correlation of protein levels (antibody-based) with transcriptomics data

  • Integration with interactome maps to place findings in pathway context

  • Comparison with phenotypic data from genetic screens

• Quantitative frameworks for data integration:

• Machine learning approaches: Supervised learning algorithms can identify patterns across datasets that may not be apparent through traditional analysis.

• Network visualization tools: Place SPAC57A7.06 findings in the context of known interaction networks to generate testable hypotheses.

This integrative approach parallels methods used in systems-level analysis of antibody responses, where multi-omics integration provided deeper insights than single-technique approaches .